A key opinion leader reviews the case of a 71-year-old woman with NTRK gene fusion thyroid cancer and considers novel therapies available for the management of her disease.
Case: A 71-Year-Old Woman With Thyroid NTRK Gene Fusion Cancer
Initial Presentation
Clinical Workup and Initial Treatment
Follow-Up and Additional Treatment
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen